NORMENT, Norwegian Centre for Mental Disorders Research, Oslo University Hospital and University of Oslo, Nydalen, P.O. Box 4956, N- 0424, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Eur Arch Psychiatry Clin Neurosci. 2024 Aug;274(5):1223-1230. doi: 10.1007/s00406-023-01591-0. Epub 2023 May 5.
Individuals with schizophrenia and bipolar disorder are at an increased risk of cardiovascular disease (CVD), and a range of biomarkers related to CVD risk have been found to be abnormal in these patients. Common genetic factors are a putative underlying mechanism, alongside lifestyle factors and antipsychotic medication. However, the extent to which the altered CVD biomarkers are related to genetic factors involved in schizophrenia and bipolar disorder is unknown. In a sample including 699 patients with schizophrenia, 391 with bipolar disorder, and 822 healthy controls, we evaluated 8 CVD risk biomarkers, including BMI, and fasting plasma levels of CVD biomarkers from a subsample. Polygenic risk scores (PGRS) were obtained from genome-wide associations studies (GWAS) of schizophrenia and bipolar disorder from the Psychiatric Genomics Consortium. The CVD biomarkers were used as outcome variables in linear regression models including schizophrenia and bipolar disorder PGRS as predictors, age, sex, diagnostic category, batch and 10 principal components as covariates, controlling for multiple testing by Bonferroni correction for the number of independent tests. Bipolar disorder PGRS was significantly (p = 0.03) negatively associated with BMI after multiple testing correction, and schizophrenia PGRS was nominally negatively associated with BMI. There were no other significant associations between bipolar or schizophrenia PGRS, and other investigated CVD biomarkers. Despite a range of abnormal CVD risk biomarkers in psychotic disorders, we only found a significant negative association between bipolar disorder PGRS and BMI. This has previously been shown for schizophrenia PGRS and BMI, and warrants further exploration.
精神分裂症和双相情感障碍患者心血管疾病 (CVD) 的风险增加，并且这些患者中与 CVD 风险相关的一系列生物标志物已被发现异常。共同的遗传因素是一种潜在的潜在机制，以及生活方式因素和抗精神病药物。然而，改变的 CVD 生物标志物与精神分裂症和双相情感障碍相关的遗传因素的程度尚不清楚。在包括 699 例精神分裂症患者、391 例双相情感障碍患者和 822 例健康对照的样本中，我们评估了 8 种 CVD 风险生物标志物，包括 BMI 和 CVD 生物标志物的空腹血浆水平来自子样本。多基因风险评分 (PGRS) 是从精神疾病基因组学联盟的精神分裂症和双相情感障碍全基因组关联研究 (GWAS) 中获得的。CVD 生物标志物作为因变量，将精神分裂症和双相情感障碍 PGRS 作为预测因子，年龄、性别、诊断类别、批次和 10 个主成分作为协变量，通过 Bonferroni 校正对独立测试的数量进行多重检验控制。经过多次测试校正后，双相情感障碍 PGRS 与 BMI 呈显著负相关（p=0.03），精神分裂症 PGRS 与 BMI 呈负相关。双相或精神分裂症 PGRS 与其他研究的 CVD 生物标志物之间没有其他显著关联。尽管精神障碍患者存在一系列异常的 CVD 风险生物标志物，但我们仅发现双相情感障碍 PGRS 与 BMI 之间存在显著负相关。这以前曾在精神分裂症 PGRS 和 BMI 中显示过，值得进一步探索。
